Kuros Biosciences Ltd
KURN
ISIN CH0325814116 / Valor 32581411
Kuros Biosciences Ltd
UMushroom community rating:
About company
Kuros Biosciences Ltd is a Swiss-headquartered global innovation company with extensive research experience in the field of biologics for spinal fusion. With a commercial and research presence across three continents and in 19 markets, the company is a key player in the development of advanced biologic solutions for spinal fusion procedures. With a strong focus on innovation and research, Kuros Biosciences Ltd is dedicated to improving patient outcomes and advancing the field of biologics in spinal surgery.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (20.08.2024):
Revenue Growth
Kuros Biosciences Ltd reported a significant increase in revenue for Q1 2024. Direct MagnetOs sales rose by 155% to CHF 13.9 million, compared to CHF 5.4 million in Q1 2023. This growth highlights the company's successful expansion in the market and increased demand for its products.
Segment Sales
The total sales for Kuros Biosciences Ltd's Medical Devices segment accelerated to CHF 13.9 million in Q1 2024, up from CHF 5.6 million in Q1 2023. This substantial increase underscores the strong performance and market acceptance of the company's medical devices.
EBITDA Improvement
Kuros Biosciences Ltd's Medical Devices segment achieved a positive EBITDA of CHF 3.9 million in Q1 2024, a significant improvement from CHF 0.5 million in Q1 2023. This positive EBITDA indicates better operational efficiency and profitability within the segment.
Net Loss Reduction
The net loss for Kuros Biosciences Ltd in Q1 2024 was CHF 0.2 million, a notable reduction from the CHF 5.1 million net loss reported in Q1 2023. This reduction in net loss reflects the company's improved financial health and operational performance.
Cash Position
As of June 30, 2024, Kuros Biosciences Ltd reported cash and cash equivalents amounting to CHF 14.3 million, slightly up from CHF 14.2 million as of December 31, 2023. This stable cash position ensures the company has sufficient liquidity to support its ongoing operations and growth initiatives.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
942 M
Market cap (USD)
494,670
Daily traded volume (Shares)
24.95 / 22.95
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
